Spots Global Cancer Trial Database for PARP Inhibition for Gliomas (PI-4G or π4g)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PARP Inhibition for Gliomas (PI-4G or π4g)
Official Title: Phase II Trial of Niraparib in Patients With Recurrent Glioma
Study ID: NCT05297864
Interventions
Study Description
Brief Summary: The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
Detailed Description: Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive treatment with niraparib in the form of capsules taken every day for the first 28 days. If this dose is tolerated well, the patients will continue to take the capsules and more patients will be enrolled on the study. Patients will continue treatment with niraparib while on the study unless there is evidence of tumor growth or they experience unacceptable side effects. Patients will be monitored during treatment with tests and exams and after treatment completion for up to four years from the time they enrolled on the study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Contact Details
Name: James Battiste, MD
Affiliation: Stephenson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
